CompletedPhase 3NCT01041573

Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population

Studying Encephalitis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Valneva Austria GmbH
Principal Investigator
Vera Kadlecek
Valneva Austria GmbH
Intervention
IC51 Japanese Encephalitis(biological)
Enrollment
1869 enrolled
Eligibility
18 years · All sexes
Timeline
20102011

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01041573 on ClinicalTrials.gov

Other trials for Encephalitis

Additional recruiting or active studies for the same condition.

See all trials for Encephalitis

← Back to all trials